Treating psychosis in movement disorder patients: a review

Bibliography

• Friedman JH. Parkinson disease psychosis: an update. Exp Opin Pharmacother 2013;14:1969-75
   PubMed Web of Science ®Google Scholar
• Mack J, Rabins P, Anderson K, et al. Prevalence of psychotic symptoms in a community based Parkinson disease sample. Am J Ger Psychiatry 2012;20(2):123-32
   PubMed Web of Science ®Google Scholar
• Diederich NJ, Fenelon G, Stebbins G, Goetz CG. Hallucinations in Parkinson disease. Nat Rev Neurol 2009;5(6):331-42
   PubMed Web of Science ®Google Scholar
• McKeith IG. Consensus guideline for the clinical and pathologic diagnosis of dementia with Lewy bodies: report of the consortium on DLB international workshop. J Alz Dis 2006;9(Suppl 3):417-23
   Google Scholar
• Frank S. Treatment of Huntington’s disease. Neurother 2014;11:153-60
   PubMed Web of Science ®Google Scholar
• Marsden CK, Mindham RHS, MacKay AVP. Extrapyramidal movement disorders produced by antipsychotic drugs. In: Bradley PD, Hirsch SR, editors. The psychopharmacology and treatment of schizophrenia. Oxford University Press, Oxford, England; 1986. p. 340-402
   Google Scholar
• Hardie RJ, Lees AJ. Neuroleptic induced Parkinson’s syndrome: clinical features and results of treatment with levodopa. J Neurol Neurosurg Psychiatry 1988;51:850-4
   PubMed Web of Science ®Google Scholar
• Friedman JH. Drug induced parkinsonism. Medlink 2014
   Google Scholar
• Stroup TS, Lieberman JA, McEvoy JP, et al. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry 2006;163(4):611-22
   PubMed Web of Science ®Google Scholar
• Margolis R, O’Hearn E, Rosenblatt A, et al. A disorder similar to Huntington’s disease is associated with a novel CAG repeat expansion. Ann Neurol 2001;373-80
   Google Scholar
• Margolis RL, Holmes SE, Rosenblatt A, et al. Huntington’s Disease like-2 (HDL2) in North America and Japan. Ann Neurol 2004;56:670-4
   Google Scholar
• Bardien S, Abrahams F, Soodyall H, et al. A South African mixed ancestry family with Huntington disease-like 2; clinical and genetic features. Mov Disord 2007;22:2083-9
   Google Scholar
• Rodrigues GR, Walker RH, Brice A, et al. Huntington’s disease like 2 in Brazil-report of 4 patients. Mov Disord 2008;23:2244-7
   Google Scholar
• Walterfang M, Evans A, Looi JC, et al. The neuropsychiatry of neuroacanthocytosis syndromes. Neurosci Biobehav Rev 2011;35(5):1275-83
   Google Scholar
• Goetz CG. Hallucinations in Parkinson’s disease: the clinical syndrome. Adv Neurol 1999;80:419-23
   PubMedGoogle Scholar
• Chou KL, Messing S, Oakes D, et al. Drug-induced psychosis in Parkinson disease: phenomenology and correlations among psychosis rating instruments. Clin Neuropharmacol 2005;28(5):215-19
   PubMed Web of Science ®Google Scholar
• Goetz CG, Tanner CM, Klawans HL. Pharmacology of hallucinations induced by long-term therapy. Am J Psychiatry 1982;139(4):494-7
   PubMed Web of Science ®Google Scholar
• Goetz CG, Stebbins GT. Risk factors for nursing home placement in advanced Parkinson’s disease. Neurol 1993;43(11):2227-9
   PubMed Web of Science ®Google Scholar
• Friedman JH. The management of the levodopa psychoses. Clin Neuropharmacol 1991;14(4):283-95
   Google Scholar
• Trosch RM, Friedman JH, Lannon MC, et al. Clozapine use in Parkinson’s disease: a retrospective analysis of a large multi-centered clinical experience. Mov Disord 1998;13(3):377-82
   PubMed Web of Science ®Google Scholar
• Ostergaard K, Dupont E. Clozapine treatment of drug induced psychosis in late stages of Parkinson’s disease. Acta Neurol Scand 1988;78(4):349-50
   PubMed Web of Science ®Google Scholar
• Roberts HE, Dean RC, Stoudemire A. Clozapine treatment of psychosis in Parkinson’s disease. J Neuropsychiatry Clin Neurosci 1989;1(2):190-2
   Google Scholar
• Lew MF, Waters CH. Clozapine treatment of parkinsonism with psychosis. J Am Ger Soc 1993;41(6):669-71
   Google Scholar
• Greene P, Cote L, Fahn S. Treatment of drug-induced psychosis in Parkinson’s disease with clozapine. Adv Neurol 1993;60:703-6
   PubMedGoogle Scholar
• Pakkenberg H, Pakkenberg B. Clozapine in the treatment of tremor. Acta Neurol Scand 1986;73(3):295-7
   PubMedGoogle Scholar
• Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson’s disease. The Parkinson Study Group. N Engl J Med 1999;340(10):757-63
   PubMed Web of Science ®Google Scholar
• Pollak P, Tison F, Rascol O, et al. Clozapine in drug induced psychosis in Parkinson’s disease: a randomised, placebo controlled study with open follow up. J Neurol Neurosurg Psychiatry 2004;75(5):689
   PubMed Web of Science ®Google Scholar
• Fernandez HH, Friedman JH, Lansang MC, et al. Diabetes mellitus among parkinsonian patients treated chronically with clozapine. Park Rel Disord 2004;10(7):439
   Google Scholar
• Thomas AA, Friedman JH. Current use of clozapine in Parkinson’s disease and related disorders. Clin Neuropharmacol 2010;33(1):14
   Google Scholar
• Friedman JH, Lannon MC. Clozapine-responsive tremor in Parkinson’s disease. Mov Disord 1990;5(3):225
   Google Scholar
• Jansen EN. Clozapine in the treatment of tremor in Parkinson’s disease. Acta Neurol Scand 1994;89(4):262-5
   PubMed Web of Science ®Google Scholar
• Bennett JA Jr, Landow ER, Dietrich S, Schuh LA. Suppression of dyskinesias in advanced Parkinson disease: moderate daily doses of clozapine provide long-term dyskinesia reduction. Mov Disord 1994;9:409-14
   PubMed Web of Science ®Google Scholar
• Bennett JA Jr, Landow ER, Schuh LT. Suppression of dyskinesias in advanced Parkinson’s disease II: increasing daily clozapine doses suppress dyskinesias and improve parkinsonism symptoms. Neurol 1993;43:1551-5
   Google Scholar
• Ondo WG, Tintner R, Vuong KD, et al. Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson’s disease. Mov Disord 2005;20(8):958-63
   PubMed Web of Science ®Google Scholar
• Rabey JM, Prohorov T, Miniovich A, Klein C. The effect of quetiapine in Parkinson’s disease (PD) psychotic patients: a double-blind labeled study of three months duration. Mov Disord 2007;22(3):313-18
   PubMed Web of Science ®Google Scholar
• Shotbolt P, Samuel M, Fox C, David AS. A randomized controlled trial of quetiapine for psychosis in Parkinson’s disease. Neuropsychiatr Dis Treat 2009;5:327-32
   PubMed Web of Science ®Google Scholar
• Fernandez HH, Okun MS, Rodriguez RL, et al. Quetiapine improves visual hallucinations in Parkinson’s disease but not through normalization of sleep architecture: results of a double blind clinical-polysomnograph study. Int J Neurosci 2009;119(12):2196-205
   PubMed Web of Science ®Google Scholar
• Prohorov T, Klein C, Miniovitz A, et al. The effect of quetiapine in psychotic Parkinson patients with and without dementia. An open label study using a structured interview. J Neurol 2006;253(2):171-5
   PubMed Web of Science ®Google Scholar
• Fernandez HH, Friedman JH, Jacques C, Rosenfeld M. Quetiapine for the treatment of drug induced psychosis in Parkinson’s disease. Mov Disord 1999;14(3):484-7
   PubMed Web of Science ®Google Scholar
• Ondo WG, Levy JK, Vuong KD, et al. Olanzapine treatment for dopaminergic-hallucinations. Mov Disord. 2002;17(5):1031-5
   Google Scholar
• Breier A, Sutton VK, Feldman PD, et al. Olanzapine in the treatment of dopamimetic-induced psychosis in patient with Parkinson’s disease. Biol Psych. 2002;52(5):438-45
   Google Scholar
• Goetz CG, Blasucci LM, Leurgans S, Pappert EJ. Olanzapine and clozapine: comparative effects on motor function in hallucinating PD patients. Neurology 2000;55(6):789-94
   PubMed Web of Science ®Google Scholar
• Friedman JH, Goldstein S, Jacques C. Substituting clozapine for olanzapine in psychiatrically stable Parkinson’s disease patients: results of an open label pilot study. Clin Neuropharmacol 1998;21(5):285-8
   Google Scholar
• Ford B, Lynch T, Greene P. Risperidone in Parkinson’s disease. Lancet 1994;344(8923):681
   PubMed Web of Science ®Google Scholar
• Rich SS, Friedman JH, Ott BR. Risperidone versus clozapine in the treatment of psychosis in six patients with Parkinson’s disease and other akinetic-rigid syndromes. J Clin Psychiatry 1995;56(12):556-9
   PubMed Web of Science ®Google Scholar
• Berkowitz AL. Ziprasidone therapy in elderly patients with psychotic mood disorders and Parkinson’s disease. Psychiatry (Edgemont)2006;3(11):59-63
   Google Scholar
• Friedman JH, Berman RM, Goetz CG, et al. Open-label flexible-dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson’s disease. Mov Disord 2006;21(12):2078-81
   PubMed Web of Science ®Google Scholar
• Schindehutte J, Trenkwalder C. Treatment of drug-induced psychosis in Parkinson’s disease with ziprasidone can induce severe dose-dependent off-periods and pathological laughing. Clin Neurol Neurosurg 2007;109(2):188-91
   PubMed Web of Science ®Google Scholar
• Rocha FL, Hara C, Ramos MG, et al. An exploratory open label trial of ziprasidone for the treatment of behavioral and psychological symptoms of dementia. Dement Geriatr Cogn Disord 2006;22(5-6):445-8
   Google Scholar
• Workman RH Jr, Orengo CA, Bakey AA, et al. The use of risperidone for psychosis and agitation in demented patients with Parkinson’s disease. J Neuropsych Clin Neurosci 1997;9(4):594-7
   Google Scholar
• Michelli F, Taubenslag N, Gatta E, Scorticati MC. Ziprasidone in pysychosis in Parkinson’s disease. Clin Neuropharmacol 2005;28(5):254
   Google Scholar
• Duran-Ferreras E, Alvarez-Lopez M, Gartcia-Moreno JM, Chacon J. Ziprasidone in parkinsonian dopamine psychosis. Rev Neurol 2008;46(8):476-80
   Google Scholar
• Wolters EC, Jansen EN, Tuynman-Qua HG, Bergman PL. Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson’s disease. Neurology 1996;47(4):1085-7
   PubMed Web of Science ®Google Scholar
• Meltzer HY, Mills R, Revell S, et al. Pimvanserin, a serotonin (5A) receptor inverse agonist for the treatment of Parkinson’s disease psychosis. Neuropsychopharmacol 2010;35:881-92
   PubMed Web of Science ®Google Scholar
• Cummings J, Isaacson S, Mills R, et al. Pimavanserin for patients with Parkinson disease psychosis: a randomized, placebo-controlled phase 3 trial. Lancet 2014;383:533-40
   PubMed Web of Science ®Google Scholar
• Friedman JH. Pimvanserin for the treatment of Parkinson’s disease psychosis. Exp Opin Pharmacother 2013;14:1969-75
   PubMed Web of Science ®Google Scholar
• Ibarretxe-Bilbao N, Junque C, Marti MJ, Tolosa E. Cerebral basis of visual hallucinations in Parkinson’s disease: structural and functional MRI studies. J Neurol Sci 2011;310:79-81
   Google Scholar
• Lee WJ, Tsai CF, Gautheir S, et al. The association between cognitive impairment and neuropsychiatric symptoms in patients with Parkinson’s disease dementia. Int Psychogeriatr 2012;24:1980-7
   Google Scholar
• Hepp DH, da Hora CC, Loene T. Cognitive correlates of visual hallucinations in on-demented Parkinson’s disease patients. Park Rel Dis 2013;19:795-9
   PubMed Web of Science ®Google Scholar
• Sobow T. Parkinson’s disease related visual hallucinations unresponsive to atypical antipsychotics treated with cholinesterase inhibitors: a case series. Neurol Neurochir Pol 2007;41(3):276-9
   Google Scholar
• Bergman J, Lerner V. Successful use of donepezil for the treatment of psychotic symptoms in patient with Parkinson’s disease. Clin Neuropharmacol 2002;25(3):107-10
   Google Scholar
• Reading PJ, Luce AK, McKeith IG. Rivastigmine in the treatment of Parkinson psychosis and cognitive impairment: preliminary findings from an open trial. Mov Disord 2001;16(6):1171-4
   PubMed Web of Science ®Google Scholar
• Ueda S, Koyama K, Okubo Y. Marked improvement of psychotic symptoms after electroconvulsive therapy in Parkinson disease. J ECT 2010;26(2):111-15
   PubMed Web of Science ®Google Scholar
• Usui C, Hatta K, Doi N, et al. Improvements in both psychiatric and motor signs in Parkinson’s disease, and changes in cerebral regional blood flow after electroconvulsive therapy. Prog Neuropsychopharmacol Biol Psychiatry 2011;35(7):1704-8
   PubMed Web of Science ®Google Scholar
• Muralidharam K, Thimmaiah R, Chakraborty V, Jain S. Bifrontal ECT for drug induced psychosis in Parkinson’s disease. Ind J Psychiatry 2011;53(2):156-8
   Google Scholar
• Factor SA, Molho ES, Brown DL. Combined clozapine and ECT for the treatment of drug induced psychosis in Parkinson’s disease. J Neuropsychiatry and Clin Neurosci 1995;7(3):304-7
   Google Scholar
• Culo S, Mulsant BH, Rosen J, et al. Treating neuropsychiatric symptoms in Dementia with Lewy Bodies: a randomized controlled trial. Alz Dis Assoc Disord 2010;24:360-4
   PubMed Web of Science ®Google Scholar
• Ballard C, Aarsland D, Francis P, Corbett A. Neuropsychiatric symptoms in patients associated with cortical Lewy bodies: pathophysiology, clinical features and pharmacologic management. Drugs Aging 2013;30:603-11
   PubMed Web of Science ®Google Scholar
• Thompson JC, Harris J, Sollom AC, et al. Longitudinal evaluation of neuropsychiatric symptoms in Huntington’s disease. J Neuropsychiatry Clin Neurosci 2012;24:53-60
   PubMed Web of Science ®Google Scholar
• Paulsen JS, Ready RE, Hamilton JM, et al. Neuropsychiatric aspects of Huntington’s disease. J Neurol Neurosurg Psychiatry 2001;71:310-14
   PubMed Web of Science ®Google Scholar
• Crauford D, Thompson JC, Snowden JS. Behavioral changes in Huntington disease. Neuropsychiatry Neuropsychol Behav Neurol 2001;14:219-26
   Google Scholar
• Lovestone S, Hodgson S, Sham P, et al. Familial psychiatric presentation of Huntington’s disease. J Med Genet 1996;33:128-31
   Google Scholar
• Tsuang D, DiGiacomo L, Lipe H, et al. Familial aggregation of schizophrenia-like symptoms in Huntington’s disease. Am J Med Genet 1999;81:323-7
   Google Scholar
• Tsuang D, Almqvist EW, Lipe H, et al. Familial aggregation of psychotic symptoms in Huntington’s disease. Am J Psychiatry 2000;157:1955-9
   Google Scholar
• Killoran A, Biglan KM. Therapeutics in Huntington’s disease. Curr Treat Options Neurol 2012;14:137-49
   Web of Science ®Google Scholar
• Oulis P, Mourikis I, Konstantakopolous G, et al. Aripiprazole in the treatment of olanzapine-resistant psychotic and motor symptoms of Huntington’s disease. J Neuropsychiatry Clin Neurosci 2010;22:352c.e4-352.e5
   Google Scholar
• LeWitt PA. Tardive dyskinesia caused by tetrabenazine. Clin Neuropharmacol 2013;36:92-3
   PubMed Web of Science ®Google Scholar
• Duff K, Beglinder LJ, O’Rourke ME, et al. Risperidone and the treatment of psychiatric, motor and cognitive symptoms in Huntington’s disease. Ann Clin Psychiatry 2008;20:1-3
   PubMed Web of Science ®Google Scholar
• Machusoodanan S, Brenner R. Use of risperidone in psychosis associated with Huntington’s disease. Am J Geriatr Psychiatry 2010;6:347-9
   Google Scholar
• Parsa M, Szigethy E, Voci JM, et al. Risperidone in treatment of choreoathetosis in Huntington’s Disease. J Clin Psychopharmacol 1997;17:134-5
   PubMed Web of Science ®Google Scholar
• Johnston TG. Risperidone long-acting injection and Huntington’s disease: case series with significant psychiatric and behavioural symptoms. Int Clin Psychopharmacol 2011;26:114-19
   PubMed Web of Science ®Google Scholar
• Squitieri F, Cannella M, Piorcellini A, et al. Short-term effects of olanzapine in Huntington’s disease. Neuropsychiatry Neuropsychol Behav Neurol 2001;14:69-72
   PubMedGoogle Scholar
• Alpay M, Koroshetz WJ. Quetiapine in the treatment of behavioral disturbances in patients with Huntington’s disease. Psychosomatics 2006;47:70-2
   PubMed Web of Science ®Google Scholar
• Lin WC, Chou YH. Aripiprazole effects on psychosis and chorea in a patient with Huntington’s disease. Am J Psychiatry 2008;165:1207-8
   PubMed Web of Science ®Google Scholar
• van Vugt JP, Siesling S, Vergeer M, et al. Clozapine versus placebo in Huntington’s disease: a double blind randomised comparative study. J Neurol Neurosurg Psychiatry 1997;63:35-9
   PubMed Web of Science ®Google Scholar
• Walker RH, Jankovic J, O’Hearn E, et al. Phenotypic features of Huntington’s disease-like 2. Mov Disord 2003;18:1527-30
   Google Scholar
• Walker RH, Rasmussen A, Rudnicki D, et al. Huntington’s disease-like 2 can present as chorea-acanthocytosis. Neurology 2003;61:1002-4
   Google Scholar
• Bruneau MA, Lesperance P, Chouinard S. Schizophrenia-like presentation of neuroacanthocytosis. J Neuropsychiatry Clin Neurosci 2003;15:378-80
   Google Scholar
• Yamada H, Ohji T, Sakurai S, et al. Chorea-acanthocytosis presenting with schizophrenia symptoms as first symptoms. Psychiatry Clin Neurosci 2009;63:253-4
   Google Scholar
• Rutherford M. Use of electroconvulsive therapy in a patient with chorea neuroacanthocytosis and prominent delusions. J ECT 2012;28:e5-6
   Google Scholar
• Glazer WM, Morgenstern H, Schooler N, et al. Predictors of improvement in tardive dyskinesia following discontinuation of neuroleptic medications. Br J Psychiatry 1990;157:585-92
   PubMed Web of Science ®Google Scholar
• Fernandez HH, Krupp B, Friedman JH. The course of tardive dyskinesia and parkinsonism in psychiatric inpatients: a 14 year follow up. Neurol 2001;56:805-7
   PubMed Web of Science ®Google Scholar
• Factor SA, Steenland K, Higgins DS, et al. Disease-related and genetic correlates of psychotic symptoms in Parkinson’s disease. Mov Dis 2011;26:2190-5
   PubMed Web of Science ®Google Scholar
• Egan MF, Apud J, Wyatt RJ. Treatment of tardive dyskinesia. Schiz Bull 1997;23:583-609
   PubMed Web of Science ®Google Scholar
• Tarsy D, Baldessarini RJ. Epidemiology of tardive dyskinesia: is risk declining with atypical antipsychotics? Mov Disord 2006;21:589-98
   PubMed Web of Science ®Google Scholar
• Caroff SN, Davis VG, Miller DD, et al. Treatment Outcomes of Patients with Tardive Dyskinesia and Chronic Schizophrenia. J Clin Psychiatry 2011;72:295-303
   PubMed Web of Science ®Google Scholar
• Caroff SN, Hurford I, Lybrand J, Campbell EC. Movement disorders induced by antipsychotic drugs: implications of the CATIE Schizophrenia trial. Neurol Clin 2011;29:127-48
   PubMed Web of Science ®Google Scholar
• Weintraub D, Burn DJ. Parkinson’s disease: the quintessential neuropsychiatric disorder. Mov Disord 2011;26(6):1022-31
   PubMed Web of Science ®Google Scholar
• Kummer A, Teixeira AL. Neuropsychiatry of Parkinson’s disease. Arq Neuropsiquaitr 2009;67(3B):930-9
   PubMed Web of Science ®Google Scholar
• Gallagher DA, Lees AJ, Schrag A. What are the most important non-motor symptoms in patients with Parkinson’s disease and are we missing them? Mov Disord 2010;25(15):2493-500
   PubMed Web of Science ®Google Scholar
• Caroff SN, Miller DD, Shopesh V, Campbell EC. Tardive Dyskinesia? Decisions should be based on the course of TD and effective control of psychotic symptoms. Curr Psychiatry 2011;10:23-32
   Google Scholar
• Friedman JH, Ravina B, Mills R, et al. A multi center placebo controlled double blind trial to examine safety and efficacy of pimavanserin in the treatment of psychosis in Parkinson’s disease. American Acad of Neurology; Toronto; 2010
   Google Scholar